In this issue
Creating a stronger front against cancer: ESMO and ECCO join forces
Temsirolimus in metastatic renal cell carcinoma
UFT (tegafur–uracil) in rectal cancer
Targeting Src in breast cancer
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy
Practical guidance for the management of aromatase inhibitor-associated bone loss
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
Satisfaction with and psychological impact of immediate and deferred breast reconstruction
Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors
First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group
Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment
Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model
Effects of an endurance and resistance exercise program on persistent cancer-related fatigue after treatment
Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma
Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors?
Infusion of trastuzumab maintenance doses over 30 minutes
Large bowel perforation associated with capecitabine treatment for breast cancer
Anthracyclines for gestational breast cancer: course and outcome of pregnancy
Value of frontline autologous stem-cell transplantation in peripheral T-cell lymphoma
Stopping a trial early in oncology: for patients or for industry?